Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
CN Stock MarketDetailed Quotes
002428 Yunnan Lincang Xinyuan Germanium Industry
- 19.99
- +0.19+0.96%
Not Open Apr 1 15:00 CST
13.06BMarket Cap246.79P/E (TTM)
20.18High19.85Low152.07KlotVolume20.00Open19.80Pre Close303.91MTurnover2.33%Turnover Ratio246.79P/E (Static)653.12MShares29.6052wk High8.97P/B13.05BFloat Cap9.0852wk Low21.78Limit Up653.04MShs Float30.23Historical High17.82Limit Down1.67%Amplitude4.59Historical Low0.02Dividend TTM19.99Avg Price75.72KlotAsk0.10%Div YieldTTM100Lot Size71.56KlotBid
Yunnan Lincang Xinyuan Germanium Industry Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 14.20%767.4M | 6.74%502.76M | 23.53%348.13M | -10.32%130.65M | 25.23%671.98M | 14.18%470.99M | -9.32%281.82M | -3.34%145.67M | -3.57%536.6M | 8.82%412.5M |
| Operating revenue | 14.20%767.4M | 6.74%502.76M | 23.53%348.13M | -10.32%130.65M | 25.23%671.98M | 14.18%470.99M | -9.32%281.82M | -3.34%145.67M | -3.57%536.6M | 8.82%412.5M |
| Other operating revenue | -14.75%8.1M | ---- | 0.69%1.97M | ---- | 43.87%9.51M | ---- | -56.41%1.96M | ---- | 300.30%6.61M | ---- |
| Total operating cost | 7.14%751.69M | -0.54%501.65M | 24.08%380.21M | -4.27%155.26M | 9.71%701.6M | 14.76%504.36M | -0.09%306.42M | 11.53%162.18M | 10.51%639.53M | 7.67%439.49M |
| Operating cost | 0.71%548.83M | -9.47%355.18M | 27.96%296.99M | -10.31%112.12M | 14.80%544.98M | 13.96%392.35M | -4.56%232.1M | 10.66%125M | 6.08%474.71M | 11.00%344.28M |
| Operating tax surcharges | 6.70%8.63M | 3.54%5.73M | -2.30%3.15M | -6.37%1.41M | 56.42%8.08M | 31.28%5.53M | 19.73%3.22M | 35.34%1.51M | -5.16%5.17M | 12.41%4.21M |
| Operating expense | 114.64%17.86M | 76.18%11.92M | 20.13%4.87M | 33.89%2.51M | 14.21%8.32M | 8.81%6.77M | 9.15%4.06M | -8.52%1.87M | 33.88%7.28M | 30.48%6.22M |
| Administration expense | 7.39%81.69M | 9.36%57.64M | 6.94%38.68M | 14.45%21.55M | -9.59%76.07M | 5.30%52.7M | 6.68%36.17M | 7.87%18.83M | 29.07%84.14M | 5.25%50.05M |
| Financial expense | 41.98%35.78M | 41.15%25.91M | 27.28%14.74M | 29.25%7.37M | 7.57%25.2M | 4.62%18.36M | 4.63%11.58M | -0.59%5.7M | -12.45%23.43M | -9.95%17.55M |
| -Interest expense (Financial expense) | 33.36%34.92M | 33.60%25.38M | 31.56%15.53M | 37.11%7.55M | -0.31%26.18M | -2.07%19M | -0.63%11.8M | -6.33%5.51M | -2.74%26.26M | -0.50%19.4M |
| -Interest Income (Financial expense) | 18.16%-914.28K | 73.40%-899.77K | 72.13%-512.54K | 44.51%-462.56K | 38.46%-1.12M | -60.25%-3.38M | -308.39%-1.84M | -142.67%-833.65K | -8.25%-1.82M | -159.06%-2.11M |
| Research and development | 51.26%58.9M | 58.02%45.27M | 12.94%21.78M | 11.16%10.3M | -13.07%38.94M | 66.71%28.65M | 59.06%19.28M | 51.71%9.26M | 57.91%44.8M | -23.60%17.18M |
| Credit Impairment Loss | 76.61%-2.21M | -299.57%-1.86M | -70.16%274.14K | 1,098.02%4.64M | -1,454.78%-9.46M | -139.51%-465.89K | -31.24%918.83K | -55.01%387.49K | -137.17%-608.61K | 296.63%1.18M |
| Asset Impairment Loss | -31.29%-5.9M | 95.80%-45.56K | 974.26%2.36M | ---- | 18.21%-4.49M | -806.00%-1.09M | -275.27%-269.5K | ---- | -94.85%-5.49M | -94.52%153.76K |
| Other net revenue | 25.00%41.6M | 7.52%28.98M | 13.37%20.3M | 87.26%13.23M | 22.76%33.28M | -1.62%26.95M | 2.54%17.91M | -38.31%7.06M | -47.78%27.11M | -27.57%27.39M |
| Invest income | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --942.38K | --942.38K |
| Asset deal income | -147.56%-252.28K | ---- | ---- | ---- | 1,955.48%530.43K | -24.76%103.93K | ---- | ---- | -100.78%-28.59K | -96.23%138.13K |
| Other revenue | 6.98%49.96M | 8.76%30.88M | 2.39%17.67M | 28.59%8.58M | 44.61%46.7M | 13.68%28.4M | 15.88%17.26M | -37.13%6.68M | -34.66%32.29M | -21.80%24.98M |
| Operating profit | 1,466.53%57.31M | 569.05%30.08M | -75.98%-11.77M | -20.51%-11.38M | 104.82%3.66M | -1,693.65%-6.41M | -131.05%-6.69M | -156.47%-9.45M | -355.38%-75.82M | -95.37%402.47K |
| Add:Non operating Income | 868.07%108.46K | -82.51%1.96K | -88.26%1.86K | 234,659.15%1.67K | -99.73%11.2K | -79.03%11.2K | -69.23%15.82K | -100.00%0.71 | 7,195.53%4.12M | 340.67%53.43K |
| Less:Non operating expense | 47.09%624.87K | 187.07%109.53K | 181.74%102.95K | 23,474.69%64.36K | 330.67%424.82K | -57.11%38.15K | 22,456.85%36.54K | --273 | -66.01%98.64K | 42.36%88.96K |
| Total profit | 1,650.31%56.79M | 565.41%29.98M | -76.95%-11.87M | -21.17%-11.45M | 104.52%3.24M | -1,855.31%-6.44M | -131.07%-6.71M | -156.34%-9.45M | -343.77%-71.8M | -95.75%366.94K |
| Less:Income tax cost | 238.31%8.72M | 190.04%2.9M | -102.10%-2.83M | 90.68%-77.86K | 57.39%-6.31M | -866.81%-3.22M | -215.94%-1.4M | -151.22%-835.34K | -317.69%-14.8M | 97.99%-333.54K |
| Net profit | 403.23%48.07M | 941.78%27.07M | -70.30%-9.04M | -32.02%-11.37M | 116.76%9.55M | -559.14%-3.22M | -126.03%-5.31M | -156.89%-8.61M | -351.60%-57M | -97.22%700.48K |
| Net profit from continuing operation | 403.23%48.07M | 941.78%27.07M | -70.30%-9.04M | -32.02%-11.37M | 116.74%9.55M | -559.14%-3.22M | -126.03%-5.31M | -156.89%-8.61M | -351.81%-57.05M | -97.22%700.48K |
| Net income from discontinuing operating | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --48.4K | ---- |
| Less:Minority Profit | -295.07%-5.03M | -245.76%-2.4M | -89.48%205.05K | -85.41%127.32K | -52.12%2.58M | -78.68%1.65M | -75.97%1.95M | -86.37%872.55K | -38.08%5.38M | -21.66%7.73M |
| Net profit of parent company owners | 661.28%53.1M | 706.02%29.47M | -27.39%-9.24M | -21.21%-11.5M | 111.18%6.97M | 30.79%-4.86M | -159.10%-7.26M | -208.56%-9.48M | -546.83%-62.39M | -145.74%-7.03M |
| Earning per share | ||||||||||
| Basic earning per share | 700.00%0.08 | 742.86%0.045 | -27.27%-0.014 | -20.00%-0.018 | 110.00%0.01 | 36.36%-0.007 | -157.89%-0.011 | -215.38%-0.015 | -600.00%-0.1 | -145.83%-0.011 |
| Diluted earning per share | 700.00%0.08 | 742.86%0.045 | -27.27%-0.014 | -20.00%-0.018 | 110.00%0.01 | 36.36%-0.007 | -157.89%-0.011 | -215.38%-0.015 | -600.00%-0.1 | -145.83%-0.011 |
| Other composite income | ||||||||||
| Total composite income | 403.23%48.07M | 941.78%27.07M | -70.30%-9.04M | -32.02%-11.37M | 116.76%9.55M | -559.14%-3.22M | -126.03%-5.31M | -156.89%-8.61M | -351.60%-57M | -97.22%700.48K |
| Total composite income of parent company owners | 661.28%53.1M | 706.02%29.47M | -27.39%-9.24M | -21.21%-11.5M | 111.18%6.97M | 30.79%-4.86M | -159.10%-7.26M | -208.56%-9.48M | -546.83%-62.39M | -145.74%-7.03M |
| Total composite income of minority owners | -295.07%-5.03M | -245.76%-2.4M | -89.48%205.05K | -85.41%127.32K | -52.12%2.58M | -78.68%1.65M | -75.97%1.95M | -86.37%872.55K | -38.08%5.38M | -21.66%7.73M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
| Auditor | Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- | -- | Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- | -- | Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.